vs
FIRST COMMUNITY BANKSHARES INC（FCBC）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
FIRST COMMUNITY BANKSHARES INC的季度营收约是REGENXBIO Inc.的1.4倍（$43.8M vs $30.3M），FIRST COMMUNITY BANKSHARES INC净利率更高（28.5% vs -221.3%，领先249.8%），REGENXBIO Inc.同比增速更快（43.0% vs 5.1%），FIRST COMMUNITY BANKSHARES INC自由现金流更多（$60.0M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 3.5%）
第一社区银行控股公司是美国一家银行控股公司，总部位于弗吉尼亚州，为布卢菲尔德第一社区银行的母公司。截至2012年，该集团旗下网点分布在弗吉尼亚州、西弗吉尼亚州和田纳西州，截至2023年4月，集团总资产达36亿美元。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
FCBC vs RGNX — 直观对比
营收规模更大
FCBC
是对方的1.4倍
$30.3M
营收增速更快
RGNX
高出37.9%
5.1%
净利率更高
FCBC
高出249.8%
-221.3%
自由现金流更多
FCBC
多$112.8M
$-52.8M
两年增速更快
RGNX
近两年复合增速
3.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $43.8M | $30.3M |
| 净利润 | $12.5M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 36.8% | -190.0% |
| 净利率 | 28.5% | -221.3% |
| 营收同比 | 5.1% | 43.0% |
| 净利润同比 | -4.4% | -31.2% |
| 每股收益（稀释后） | $0.67 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FCBCRGNX
| Q4 25 | $43.8M | $30.3M | ||
| Q3 25 | $42.2M | $29.7M | ||
| Q2 25 | $41.0M | $21.4M | ||
| Q1 25 | $40.5M | $89.0M | ||
| Q4 24 | $41.7M | $21.2M | ||
| Q3 24 | $42.0M | $24.2M | ||
| Q2 24 | $41.3M | $22.3M | ||
| Q1 24 | $40.9M | $15.6M |
净利润FCBCRGNX
| Q4 25 | $12.5M | $-67.1M | ||
| Q3 25 | $12.3M | $-61.9M | ||
| Q2 25 | $12.2M | $-70.9M | ||
| Q1 25 | $11.8M | $6.1M | ||
| Q4 24 | $13.0M | $-51.2M | ||
| Q3 24 | $13.0M | $-59.6M | ||
| Q2 24 | $12.7M | $-53.0M | ||
| Q1 24 | $12.8M | $-63.3M |
毛利率FCBCRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率FCBCRGNX
| Q4 25 | 36.8% | -190.0% | ||
| Q3 25 | 37.7% | -176.3% | ||
| Q2 25 | 38.6% | -296.3% | ||
| Q1 25 | 37.7% | 13.6% | ||
| Q4 24 | 39.6% | -242.1% | ||
| Q3 24 | 39.3% | -256.6% | ||
| Q2 24 | 39.3% | -251.3% | ||
| Q1 24 | 40.3% | -408.8% |
净利率FCBCRGNX
| Q4 25 | 28.5% | -221.3% | ||
| Q3 25 | 29.1% | -208.3% | ||
| Q2 25 | 29.9% | -331.8% | ||
| Q1 25 | 29.2% | 6.8% | ||
| Q4 24 | 31.3% | -241.3% | ||
| Q3 24 | 31.0% | -246.3% | ||
| Q2 24 | 30.8% | -237.7% | ||
| Q1 24 | 31.4% | -405.4% |
每股收益（稀释后）FCBCRGNX
| Q4 25 | $0.67 | $-1.30 | ||
| Q3 25 | $0.67 | $-1.20 | ||
| Q2 25 | $0.67 | $-1.38 | ||
| Q1 25 | $0.64 | $0.12 | ||
| Q4 24 | $0.67 | $-0.99 | ||
| Q3 24 | $0.71 | $-1.17 | ||
| Q2 24 | $0.71 | $-1.05 | ||
| Q1 24 | $0.71 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $500.5M | $102.7M |
| 总资产 | $3.3B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FCBCRGNX
| Q4 25 | — | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M | ||
| Q1 24 | — | $338.7M |
总债务FCBCRGNX
| Q4 25 | — | — | ||
| Q3 25 | $0 | — | ||
| Q2 25 | $0 | — | ||
| Q1 25 | $0 | — | ||
| Q4 24 | $0 | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $0 | — | ||
| Q1 24 | $0 | — |
股东权益FCBCRGNX
| Q4 25 | $500.5M | $102.7M | ||
| Q3 25 | $510.7M | $161.5M | ||
| Q2 25 | $502.8M | $213.7M | ||
| Q1 25 | $496.4M | $274.2M | ||
| Q4 24 | $526.4M | $259.7M | ||
| Q3 24 | $520.7M | $301.4M | ||
| Q2 24 | $508.9M | $348.3M | ||
| Q1 24 | $506.9M | $390.7M |
总资产FCBCRGNX
| Q4 25 | $3.3B | $453.0M | ||
| Q3 25 | $3.2B | $525.2M | ||
| Q2 25 | $3.2B | $581.0M | ||
| Q1 25 | $3.2B | $490.9M | ||
| Q4 24 | $3.3B | $466.0M | ||
| Q3 24 | $3.2B | $519.1M | ||
| Q2 24 | $3.2B | $569.4M | ||
| Q1 24 | $3.2B | $629.2M |
负债/权益比FCBCRGNX
| Q4 25 | — | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 0.00× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | 0.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $62.7M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $60.0M | $-52.8M |
| 自由现金流率自由现金流/营收 | 137.0% | -174.0% |
| 资本支出强度资本支出/营收 | 6.3% | 1.7% |
| 现金转化率经营现金流/净利润 | 5.03× | — |
| 过去12个月自由现金流最近4个季度 | $100.6M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流FCBCRGNX
| Q4 25 | $62.7M | $-52.3M | ||
| Q3 25 | $18.9M | $-56.0M | ||
| Q2 25 | $10.2M | $-49.3M | ||
| Q1 25 | $13.2M | $33.6M | ||
| Q4 24 | $57.7M | $-31.6M | ||
| Q3 24 | $11.4M | $-40.5M | ||
| Q2 24 | $14.5M | $-45.5M | ||
| Q1 24 | $16.9M | $-55.5M |
自由现金流FCBCRGNX
| Q4 25 | $60.0M | $-52.8M | ||
| Q3 25 | $18.5M | $-56.5M | ||
| Q2 25 | $10.0M | $-49.7M | ||
| Q1 25 | $12.1M | $32.6M | ||
| Q4 24 | $54.9M | $-32.7M | ||
| Q3 24 | $10.9M | $-40.9M | ||
| Q2 24 | $14.1M | $-46.0M | ||
| Q1 24 | $15.2M | $-56.0M |
自由现金流率FCBCRGNX
| Q4 25 | 137.0% | -174.0% | ||
| Q3 25 | 43.9% | -189.9% | ||
| Q2 25 | 24.3% | -232.8% | ||
| Q1 25 | 29.8% | 36.6% | ||
| Q4 24 | 131.8% | -154.2% | ||
| Q3 24 | 26.0% | -168.9% | ||
| Q2 24 | 34.1% | -206.2% | ||
| Q1 24 | 37.1% | -358.5% |
资本支出强度FCBCRGNX
| Q4 25 | 6.3% | 1.7% | ||
| Q3 25 | 1.0% | 1.7% | ||
| Q2 25 | 0.6% | 1.8% | ||
| Q1 25 | 2.8% | 1.2% | ||
| Q4 24 | 6.7% | 5.1% | ||
| Q3 24 | 1.2% | 1.3% | ||
| Q2 24 | 0.9% | 2.1% | ||
| Q1 24 | 4.4% | 3.6% |
现金转化率FCBCRGNX
| Q4 25 | 5.03× | — | ||
| Q3 25 | 1.54× | — | ||
| Q2 25 | 0.83× | — | ||
| Q1 25 | 1.12× | 5.53× | ||
| Q4 24 | 4.43× | — | ||
| Q3 24 | 0.88× | — | ||
| Q2 24 | 1.14× | — | ||
| Q1 24 | 1.32× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FCBC
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
